Alfred Sandrock Biography and Net Worth

insider of Biogen

Alfred W. Sandrock, Jr., M.D., Ph.D., is Executive Vice President, Research & Development at Biogen and has served on the Executive Committee since 2015. He has served as the head of Research & Development since October 2019 and was our Chief Medical Officer from 2012 until January 2020. Since joining the company in 1998, he has held several senior executive positions, including Senior Vice President of Development Sciences, Senior Vice President of Neurology Research and Development, and Vice President of Clinical Development, Neurology. Dr. Sandrock received his B.A. in human biology from Stanford University, an M.D. from Harvard Medical School, and a Ph.D. in neurobiology from Harvard University. He completed an internship in medicine, a residency and chief residency in neurology, and a clinical fellowship in Neuromuscular Disease and Clinical Neurophysiology (electromyography) at Massachusetts General Hospital.

What is Alfred Sandrock's net worth?: The estimated net worth of Alfred Sandrock is at least $50.20 million as of April 2nd, 2025. Dr. Sandrock owns 430,931 shares of Biogen stock worth more than $50,199,152 as of April 21st. This net worth approximation does not reflect any other assets that Dr. Sandrock may own. Learn More about Alfred Sandrock's net worth.
How do I contact Alfred Sandrock?: The corporate mailing address for Dr. Sandrock and other Biogen executives is 225 BINNEY STREET, CAMBRIDGE MA, 02142. Biogen can also be reached via phone at (617) 679-2000 and via email at ir@biogen.com. Learn More on Alfred Sandrock's contact information.
Has Alfred Sandrock been buying or selling shares of Biogen?: Alfred Sandrock has not been actively trading shares of Biogen over the course of the past ninety days. Most recently, Alfred Sandrock sold 7,672 shares of the business's stock in a transaction on Monday, June 7th. The shares were sold at an average price of $440.00, for a transaction totalling $3,375,680.00. Following the completion of the sale, the insider now directly owns 2,919 shares of the company's stock, valued at $1,284,360. Learn More on Alfred Sandrock's trading history.
Who are Biogen's active insiders?: Biogen's insider roster includes Susan Alexander (EVP), Brian Posner (Director), Eric Rowinsky (Director), Alfred Sandrock (insider), Stephen Sherwin (Director), Stephen Sherwin (Director), Stephen Sherwin (Director), Priya Singhal (Insider), and Michel Vounatsos (CEO). Learn More on Biogen's active insiders.
Are insiders buying or selling shares of Biogen?: During the last twelve months, insiders at the biotechnology company sold shares 2 times. They sold a total of 9,191 shares worth more than $1,402,194.02. The most recent insider tranaction occured on March, 7th when Director Stephen A Sherwin sold 8,760 shares worth more than $1,314,175.20. Insiders at Biogen own 0.2% of the company. Learn More about insider trades at Biogen.
Information on this page was last updated on 3/7/2025.

Alfred Sandrock Insider Trading History at Biogen

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/7/2021	Sell	7,672	$440.00	$3,375,680.00	2,919
11/4/2020	Sell	1,500	$350.00	$525,000.00
2/27/2018	Sell	259	$290.83	$75,324.97	6,553
2/20/2018	Sell	743	$292.00	$216,956.00	6,553
2/15/2018	Sell	1,294	$298.85	$386,711.90	7,296
4/3/2017	Sell	1,981	$274.08	$542,952.48	7,060
2/25/2016	Sell	182	$261.90	$47,665.80	7,989
2/17/2016	Sell	721	$256.16	$184,691.36	7,989
2/9/2016	Sell	851	$246.54	$209,805.54	7,739
12/4/2015	Sell	439	$277.00	$121,603.00	7,739
3/2/2015	Sell	3,173	$409.49	$1,299,311.77
2/10/2015	Sell	1,142	$398.11	$454,641.62
2/26/2014	Sell	1,047	$342.17	$358,251.99	21,406
2/11/2014	Sell	2,084	$314.31	$655,022.04	13,666
10/22/2013	Sell	15,029	$250.11	$3,758,903.19

Alfred Sandrock Buying and Selling Activity at Biogen

Biogen Company Overview

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $116.49

$115.45

$118.61

50 Day Range

MA: $134.29

$113.38

$150.71

2 Week Range

Now: $116.49

$110.04

$238.00

Volume

1,717,973 shs

Average Volume

1,355,486 shs

Market Capitalization

$17.05 billion

P/E Ratio

10.41

Dividend Yield

N/A

Beta

0.06